Results 221 to 230 of about 3,442,266 (302)
ABSTRACT Objectives To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS ...
Ivan Pavlovic +6 more
wiley +1 more source
Risk of new diagnoses and exacerbations of chronic conditions after SARS-CoV-2 infection: a systematic review update. [PDF]
Gaudet LA +6 more
europepmc +1 more source
Nationwide Survey of Atopic Myelitis and Plexin D1‐Immunoglobulin G‐Related Pain
ABSTRACT Objective To elucidate the features of plexin D1‐immunoglobulin (Ig)G‐associated neuropathic pain and its relationship to atopic myelitis (AM) in a nationwide Japanese survey. Methods A preliminary survey questionnaire was sent to 1574 selected departments (neurology and pediatrics/pediatric neurology) to explore the numbers of AM and plexin ...
Jun‐ichi Kira +10 more
wiley +1 more source
The Influence of Blood from Patients with Different Chronic Conditions on the Wettability of Dental Implant Surfaces. [PDF]
Čivljak T +6 more
europepmc +1 more source
Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan +22 more
wiley +1 more source
Peer Support in Chronic Conditions from the Peer Supporters' Perspective: A Systematic Review. [PDF]
Braun A, Löwe B, Uhlenbusch N.
europepmc +1 more source
Self-Management of Medications During Sick Days for Chronic Conditions: A Scoping Review. [PDF]
Truong M +5 more
europepmc +1 more source
Ageing, chronic conditions and the evolution of future drugs expenditures [PDF]
Bruno Ventelou +2 more
core

